




# Access to >100 Million Lives in Europe

## Certara Evidence & Access Real World Data Solutions



Prior to August 2017, there were only a few data sources that were easily accessible in Europe. All of these data are relatively small (approx. 5-7 million) and primary care-based databases.

Since August 2017, the French agency has made the French national healthcare systems database—SNDS data—accessible to private organisations (pharmaceutical companies need to access the data via a certified third-party), and this does not have to be through academic affiliations or following a request from an agency (EMA, HAS etc.). The access request now is required to demonstrate a scientific or medical research need rather than affiliations or requests from agencies.

**Certara Evidence & Access is proud to be the first successful non-academic applicant to get a positive response towards SNDS data access.** We have been partnering with many industry clients as a pioneer to access the new SNDS data. Combined with our own ANSER Real World Data Sets and other databases in Europe, this offers a combined population of more than 100 million lives in Europe.



### Selected Experience with Specialized EU Datasets

#### SNDS (France)

65 million lives

#### CPRD (UK)

5-7 million lives

#### German Sickness Fund

5-7 million lives

#### Nordics Databases

15 million lives

#### Hungary

9 million lives



### The SNDS data have the following characteristics:

1. 65 million lives
2. Data for 10 years is available
3. Anonymised data on:

- Socio-demographics
- Medical
- Characteristics
- Ambulatory care
- Hospitalizations
- Diagnosis
- Drugs and procedures
- Mortality data
- Costs data

The SNDS data can be extremely powerful as the database size is very large and representative of the French population, even for extremely rare diseases/presentations. With a prevalence of <1 in 10,000 general population, the SNDS can provide sample sizes of >1,000.

# THE FRENCH NATIONAL HEALTH DATA SYSTEM

## AN AMALGAMATION OF THE FOLLOWING DATA



## SENIOR REAL WORLD EVIDENCE TEAM



**Billy Amzal**

SVP, Decision and Real World Data Analytics


[billy.amzal@certara.com](mailto:billy.amzal@certara.com)



**Sumeet Bakshi**

VP, Real World Evidence Solutions

[sumeet.bakshi@certara.com](mailto:sumeet.bakshi@certara.com)



**Artak Khachatryan**

Sr. Director, Pharmacoepidemiology

[artak.khachatryan@certara.com](mailto:artak.khachatryan@certara.com)



**Nadia Quignot**

Director, Decision Analytics & Real World Evidence

[nadia.quignot@certara.com](mailto:nadia.quignot@certara.com)

“ Since 2017, [...] the collaboration with Certara’s dynamic team has always been constructive and positive, resulting in the signature of a multitude of contracts governing the provision of SNDS data for the realization of various studies in the field of health. ”

— **Julius Kemme**, French Health Insurance (CNAM, SNDS data owner)

## WHY CHOOSE CERTARA EVIDENCE & ACCESS TO GET ACCESS TO THE DATA?

- **Obtain more than access to data** – from niche needs identification, justifying access, differentiating value, quantifying an opportunity, to demonstrating benefit/risk, Certara offers real world data solutions for every need.
- Leverage our in-depth knowledge of the French context and **more than 15 years of experience conducting observational studies in France**.
- Our team of **epidemiologists, statisticians** and **real world data specialists provide expert analysis and study design services** that leverage data for various international markets.



### About Certara

At Certara, we accelerate medicines to patients, partnering with life science innovators. Together we advance modern drug development with biosimulation, regulatory science, and market access solutions.

For more information visit <https://www.certara.com/evidence-access/real-world-evidence/snds/> or email [eva-bd@certara.com](mailto:eva-bd@certara.com).